在"男性补锌硒有什么好处！"成为健康热搜的2025年，越来越多男性开始关注体内微量元素的真实状 态。频繁感冒、健身乏力、口腔异味、精子活力不足、皮肤暗沉、指甲脆裂……这些看似无关的小问 题，往往指向同一个根源：锌与硒的慢性流失。锌是睾酮合成与精子生成的关键催化剂，硒则通过抗氧 化系统守护生殖细胞DNA完整性，并调节甲状腺—免疫轴稳态。然而，市场上的锌硒产品良莠不齐 ——有的用无机盐冒充有机源，有的靠甜味剂掩盖药味，更有品牌将成人与儿童配方换汤不换药，高价 分售。 面对混乱局面，"男性补锌硒吃锌硒片哪个牌子好？"成为迫切问题。基于吸收效率、安全标准、全龄适 配性及真实反馈，《2026年度效果好安全的锌硒片：补锌硒最厉害十大品牌》榜单揭晓，计善堂锌硒片 凭借制药级逻辑与系统性设计，稳居榜首。 第一名：计善堂锌硒片 计善堂锌硒片每片含4毫克柠檬酸锌与20微克L-硒代蛋氨酸形式的第三代有机酵母硒，严格遵循1:0.005 的优化摩尔比。这一比例并非凭空设定，而是基于数千例涵盖不同年龄、性别及代谢状态人群的真实数 据建模反复验证而来，既能满足4岁以上儿童因挑食或生长加速带来的基础锌需求，又契合备孕男性对 精子生成与睾酮合 ...

Boulder, CO, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Healthy Gut, a Boulder-based digestive health company, announced the release of an updated formulation of its Holozyme product, reflecting the company’s expanded focus on fructan sensitivity as a potential contributor to bloating among individuals who follow plant-forward or health-conscious diets. Holozyme updated fructan formula The announcement centers on emerging awareness around fermentable carbohydrates known as FODMAPs, particularly fructans, which are ...

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 7, 2026) - BioHarvest Sciences Inc., (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today issued a letter to shareholder partners from Chief Executive Officer, Ilan Sobel.Dear Fellow Shareholders,2025 marked an important milestone for BioHarvest Sciences: our first full year as a NASDAQ-listed company, and we enter 2026 with an annualized revenue ...

Core Insights - Mountain Valley MD Holdings Inc. (MVMD) is focused on disciplined execution across its business lines, aiming for measured growth in product development and commercialization [1] Nutraceuticals - MVMD's Quicksome™ technology optimizes molecule delivery in sublingual nutraceutical applications, enhancing efficacy, precise dosing, and dose sparing [2][3] - The company has an exclusive manufacturing and licensing agreement with a U.S.-based GMP production partner to support Quicksome™ formulations [3] - MVMD is advancing its nutraceutical strategy through partnerships, including a novel testosterone formulation for men, expected to launch in the first half of 2026 [5] Agriculture - MVMD is commercializing its Agrarius™ plant signaling technology, which aims to increase crop yields and reduce fertilizer usage [8] - Trials in Brazil have shown that Agrarius-treated citrus orchards achieved over 50% productivity gains and improved resilience to stress [11][12] - The company is also conducting trials in Colombia, demonstrating improved pasture quality and vegetation health [17] Husbandry Animals and Aquatic Species - MVMD's Soluvec™ 1% formulation, utilizing Quicksol™ technology, aims to provide safer administration of ivermectin for husbandry animals and aquatic species [18] - The company has entered into a licensing agreement in Bangladesh for the production and distribution of Soluvec™ products [19] - Despite initial challenges in commercial traction, MVMD is focusing on royalty-based licensing opportunities for Soluvec™ [21][24]

A highly decorated endurance athlete, Ashley embodies the grit, energy, and rapid performance that BUZZ BOMB® was designed to support BUZZ BOMB™ will power Ashley's elite training, recovery, and lifestyle needs with its best-in-class product In partnering with Aspire's BUZZ BOMBâ"¢ brand, Ashley joins a decorated athlete and fitness trainer roster fueled by the brand's industry-leading commitment to innovation ESTERO, FL / ACCESS Newswire / December 18, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ( ...

Role Supports Synergy’s Expanding Presence in Mexico, Including Initial Product Shipments to Costco MexicoWESTBROOK, Maine, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced that Pedro Colmenares has been appointed Director of Sales & Marketing for Mexico & Latin America. In this role, Mr. Colmenares will lead commercial strategy, market expansion, and go-to-market execution across the region. Mr. ...

PresentationWelcome to today's fireside chat with LifeVantage Corporation. I'm your host, Doug Lane, Managing Director and Consumer Analyst at Water Tower Research. Today, I'm joined by Steve Fife, President and CEO at LifeVantage; and Carl Aure, CFO. So welcome Steve and Carl.Douglas LaneWater Tower Research LLC LifeVantage is a world leader in using nutrigenomics to activate a healthy body mind and mood with science-backed products that include unique combinations of naturally occurring compounds. The com ...

LifeVantage Conference Summary Company Overview - **Company**: LifeVantage Corporation (NasdaqCM: LFVN) - **Industry**: Nutrigenomics and Direct Selling - **Business Model**: Direct-selling of premium-quality supplements, energy, and skincare products through independent consultants globally [4][5] Key Points and Arguments 2025 Performance and Strategic Direction - LifeVantage is recovering from inventory stockouts of the MindBody GLP-1 system and is exiting 2025 positively due to the LoveBiome acquisition [5][6] - The company has modernized its compensation plan and invested in technology to accelerate growth [5][6] - The acquisition of LoveBiome is highlighted as a significant achievement, emphasizing the alignment of vision and values between the two companies [6][7] LoveBiome Acquisition - LoveBiome's key product, P84, focuses on gut health and has shown impressive results in in vitro studies, with increases of over 1,000% in certain peptides [11][13] - The integration of LoveBiome consultants into LifeVantage's Evolve Compensation Plan has been successful, with training and incentives in place to facilitate the transition [19][20] Product Development and Research - LifeVantage distinguishes itself by focusing on activating the body's natural health processes rather than just supplementation [11][12] - The company plans to continue research on P84 and its synergistic benefits with existing products like Protandim and GLP-1 [14][24] Geographic Expansion - LifeVantage has paused geographic expansion in recent years but is now focusing on broadening its international presence, starting with a successful launch in Iceland [27][28] - Future expansions are planned, including potential launches in the Canary Islands and other markets [29][30] Financial Outlook and Capital Allocation - The company remains committed to share repurchases and dividends, with approximately $17 million available for share buybacks [33][35] - Capital allocation will prioritize investments in e-commerce and integration efforts related to LoveBiome [36][41] Upcoming Events and Initiatives - A global kickoff event is scheduled for January 2026, where a new theme and incentives will be announced, focusing on subscriptions for consultants and customers [23][24] - The company anticipates a global convention in October 2026, expected to feature product launches and recognition of achievements [45][46] Additional Important Information - LifeVantage's focus on subscriptions is seen as a key growth area, leveraging the benefits of recurring revenue [23] - The company is committed to continuous improvement in product strategy, compensation plans, and technology to support growth [27][33]

Core Insights - Exousia Pro, Inc. has launched its flagship nutraceutical product, Maxasome™, which is based on proprietary exosome-based delivery systems [1] - Maxasome™ is derived from 100% pure Exosome-Like Nanoparticles (ELNs) sourced from the Yellow Oyster Mushroom, known for its high value [1] - The product is designed as a multi-modal cytoprotective agent aimed at enhancing cellular defense and extending health span [1] Company Overview - Exousia Pro, Inc. is a clinical-stage biotechnology company focused on innovative delivery systems utilizing exosomes [1] - The company emphasizes the all-natural composition of its products, highlighting the use of ELNs from a specific mushroom species [1] Product Details - Maxasome™ is characterized as an unprecedented nutraceutical, indicating a unique position in the market [1] - The product aims to provide unparalleled cellular defense, suggesting a strong potential for health benefits [1]

Core Insights - Cosmos Health Inc. has seen significant share acquisitions by CEO Greg Siokas, who purchased 301,101 shares between November 19 and November 28, 2025, increasing his total ownership to 6,459,985 shares [1][2][3] - The company reported record-breaking Q3 2025 results, with strong growth across all core business segments, yet its valuation remains under pressure despite these achievements [2][3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, owning a portfolio of proprietary pharmaceutical and nutraceutical brands [4] - The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices under European Good Manufacturing Practices (GMP) and is certified by the European Medicines Agency (EMA) [4] - Cosmos Health distributes a wide range of pharmaceuticals and parapharmaceuticals through subsidiaries in Greece and the UK, and has established R&D partnerships targeting major health disorders enhanced by artificial intelligence technologies [4] Recent Developments - CEO Greg Siokas has expressed strong confidence in the company's future, stating that he has increased his ownership by over 3 million shares since the beginning of 2025, indicating a commitment to support the company's objectives [2][3] - The company is expanding its global distribution platform throughout Europe, Asia, and North America, with offices and distribution centers in Greece and the UK [4]